JP7538541B2 - 置換されたアミノチオール及びアミノジスルフィド化合物、及びそれらの使用 - Google Patents

置換されたアミノチオール及びアミノジスルフィド化合物、及びそれらの使用 Download PDF

Info

Publication number
JP7538541B2
JP7538541B2 JP2021555221A JP2021555221A JP7538541B2 JP 7538541 B2 JP7538541 B2 JP 7538541B2 JP 2021555221 A JP2021555221 A JP 2021555221A JP 2021555221 A JP2021555221 A JP 2021555221A JP 7538541 B2 JP7538541 B2 JP 7538541B2
Authority
JP
Japan
Prior art keywords
compound
cystamine
cysteamine
pharmaceutical composition
deuterated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021555221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525148A (ja
JPWO2020198529A5 (enExample
Inventor
ドヒル、ランジャン
バラトーレ、カルロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022525148A publication Critical patent/JP2022525148A/ja
Publication of JPWO2020198529A5 publication Critical patent/JPWO2020198529A5/ja
Application granted granted Critical
Publication of JP7538541B2 publication Critical patent/JP7538541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021555221A 2019-03-26 2020-03-26 置換されたアミノチオール及びアミノジスルフィド化合物、及びそれらの使用 Active JP7538541B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823892P 2019-03-26 2019-03-26
US62/823,892 2019-03-26
PCT/US2020/025067 WO2020198529A1 (en) 2019-03-26 2020-03-26 Substituted amino-thiol and amino-disulfide compounds, and uses thereof

Publications (3)

Publication Number Publication Date
JP2022525148A JP2022525148A (ja) 2022-05-11
JPWO2020198529A5 JPWO2020198529A5 (enExample) 2023-03-16
JP7538541B2 true JP7538541B2 (ja) 2024-08-22

Family

ID=72610131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555221A Active JP7538541B2 (ja) 2019-03-26 2020-03-26 置換されたアミノチオール及びアミノジスルフィド化合物、及びそれらの使用

Country Status (5)

Country Link
US (1) US12391643B2 (enExample)
EP (1) EP3946298A4 (enExample)
JP (1) JP7538541B2 (enExample)
CN (1) CN113613642B (enExample)
WO (1) WO2020198529A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265583A1 (en) * 2019-07-30 2022-08-25 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN115745857B (zh) * 2022-10-28 2025-10-17 中国医学科学院放射医学研究所 一类口服给药的活性氧响应的硫酯类化合物、合成方法及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505375A (ja) 2007-11-30 2011-02-24 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法
JP2014508758A (ja) 2011-02-23 2014-04-10 ユニバルシテ ラバル パーキンソン病を治療するためのシスタミン類似体
JP2017533967A (ja) 2014-11-05 2017-11-16 ホライズン オーファン エルエルシー システアミン組成物を用いるハンチントン病の処置方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254730A (en) * 1992-01-14 1993-10-19 Kilgore James L Production of amino acids and amino acid derivatives bearing isotopic hydrogen labels
EA201600089A1 (ru) 2006-01-27 2017-01-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Покрытые энтеросолюбильной оболочкой цистеамин и цистамин и их производные
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US8530479B2 (en) * 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
CN109310653A (zh) * 2016-03-17 2019-02-05 硫创治疗公司 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物
US20220265583A1 (en) * 2019-07-30 2022-08-25 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505375A (ja) 2007-11-30 2011-02-24 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法
JP2014508758A (ja) 2011-02-23 2014-04-10 ユニバルシテ ラバル パーキンソン病を治療するためのシスタミン類似体
JP2017533967A (ja) 2014-11-05 2017-11-16 ホライズン オーファン エルエルシー システアミン組成物を用いるハンチントン病の処置方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Glob. J. Pharmaceu. Sci.，2017年，1(4)，79-90(0001/0011-0011/0011)
REGISTRY(STN)[online]，検索日2024年2月28日: 2010. 4.21 RN:1219805-04-5

Also Published As

Publication number Publication date
CN113613642B (zh) 2024-08-06
JP2022525148A (ja) 2022-05-11
US12391643B2 (en) 2025-08-19
US20220135524A1 (en) 2022-05-05
WO2020198529A1 (en) 2020-10-01
EP3946298A4 (en) 2023-01-25
EP3946298A1 (en) 2022-02-09
CN113613642A (zh) 2021-11-05

Similar Documents

Publication Publication Date Title
AU2019222911B2 (en) Berberine salts, ursodeoxycholic salts and combinations, methods of prepration and application thereof
JP6841821B2 (ja) てんかん、嗜癖および肝細胞癌の処置のためのｇａｂａアミノトランスフェラーゼ不活性化剤としての（ｓ）−３−アミノ−４−（ジフルオロメチレニル）シクロペント−１−エン−１−カルボン酸および関連化合物
CN115490681B (zh) 三嗪衍生物
JP2023055851A (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体
JP7538541B2 (ja) 置換されたアミノチオール及びアミノジスルフィド化合物、及びそれらの使用
CN105142628A (zh) 氘取代的富马酸盐衍生物
ES2268441T3 (es) 3-ariltio-3-tiazolil-alquilaminas antiinflamatorias.
GB2603330A (en) Heterocyclic THR-# receptor agonist compound and preparation method and use therefor
TW201927368A (zh) 肌酸前驅藥、組成物及其使用方法
US20250066292A1 (en) Cysteamine and/or cystamine prodrugs
US20190381028A1 (en) Pharmaceutical composition for the treatment of parkinson's disease
CA3198659A1 (en) Methods for reversing hepatic steatosis
EP3323415A1 (en) Treatment of neurodegenerative diseases
JP7670687B2 (ja) 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用
US20250002490A1 (en) Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
JP2011190257A (ja) 組織線維化疾患の予防または治療剤
WO2025199211A1 (en) Imidazopyridines and imidazopyrimidines, and methods of using same
WO2024098856A1 (zh) 一种抗流感病毒衍生物及其用途
CN118324832A (zh) 一种核苷衍生物及其在制备抗病毒药物中的应用
WO2025127097A1 (ja) 脂肪性肝疾患の治療用医薬
WO2021222308A1 (en) Ssao inhibitors for the treatment of disease
HK1160792A (en) Hepatoprotectant acetaminophen mutual prodrugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240802

R150 Certificate of patent or registration of utility model

Ref document number: 7538541

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150